News articles about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the company an impact score of 46.0804712265824 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
- Attractive Healthcare stock of Yesterday – Novo Nordisk A/S (NVO) – Nasdaq Fortune (press release) (nasdaqfortune.com)
- How Novo Nordisk Performed in 3Q17 (finance.yahoo.com)
- Can Merck Regain its Mojo in 2018 After an Unimpressive '17? (finance.yahoo.com)
- Form 6-K NOVO NORDISK AS For: Jan 02 – StreetInsider.com (streetinsider.com)
- Novo Nordisk A/S: Status regarding Novo Nordisk’s holding of its own shares (31 December 2017) – GlobeNewswire (press release) (globenewswire.com)
Shares of Novo Nordisk A/S (NYSE:NVO) traded up $0.25 during trading hours on Friday, reaching $54.74. The company had a trading volume of 645,393 shares, compared to its average volume of 839,702. Novo Nordisk A/S has a 12 month low of $32.83 and a 12 month high of $54.76. The firm has a market cap of $139,587.00, a price-to-earnings ratio of 23.90, a P/E/G ratio of 3.06 and a beta of 0.63.
In other Novo Nordisk A/S news, insider Eric S. Sprott bought 50,000 shares of Novo Nordisk A/S stock in a transaction that occurred on Wednesday, November 8th. The shares were bought at an average cost of $8.34 per share, with a total value of $417,000.00. Corporate insiders own 0.07% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Novo Nordisk A/S (NVO) Receiving Somewhat Positive News Coverage, Analysis Shows” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The original version of this report can be accessed at https://www.com-unik.info/2018/01/07/novo-nordisk-as-nvo-receiving-somewhat-positive-news-coverage-analysis-shows.html.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.
What are top analysts saying about Novo Nordisk A/S? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Novo Nordisk A/S and related companies.